TAK-020

CAS No. 1627603-21-7

TAK-020( —— )

Catalog No. M37633 CAS No. 1627603-21-7

TAK-020 is a potent covalent inhibitor of Btk with potential antitumor activity for the study of rheumatoid arthritis and immune-related diseases.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 225 In Stock
5MG 353 In Stock
10MG 630 In Stock
25MG 1260 In Stock
50MG 1950 In Stock
100MG 2952 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    TAK-020
  • Note
    Research use only, not for human use.
  • Brief Description
    TAK-020 is a potent covalent inhibitor of Btk with potential antitumor activity for the study of rheumatoid arthritis and immune-related diseases.
  • Description
    TAK-020 is a covalent Btk inhibitor, which becomes the clinical candidate.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Tyrosine Kinase
  • Target
    BTK
  • Recptor
    BTK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1627603-21-7
  • Formula Weight
    351.36
  • Molecular Formula
    C18H17N5O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 20.83 mg/mL (59.28 mM; Ultrasonic (<80°C)
  • SMILES
    C=CC(=O)N1CC[C@@H](C1)Oc1nc(cc2ccccc12)-c1nc(=O)[nH][nH]1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Sabat M, et al. Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one, by Fragment-Based Drug Design. J Med Chem. 2021 Sep 9;64(17):12893-12902. ?
molnova catalog
related products
  • G-744

    G-744 is a highly potent, selective inhibitor of BTK with biochemical Ki of 1.28 nM.

  • Ibrutinib deacryloyl...

    Ibrutinib deacryloylpiperidine is a highly selective Bruton’s tyrosine kinase (BTK) irreversible inhibitor with an IC50 of 0.5 nM.

  • Fenebrutinib

    An orally bioavailable, selective, non-covalent and reversible BTK inhibitor with IC50 of 2-9 nM.